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Familial Dilated Cardiomyopathy
Caused by an Alpha-Tropomyosin Mutation
The Distinctive Natural History
of Sarcomeric Dilated Cardiomyopathy
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Objectives We sought to further define the role of sarcomere mutations in dilated cardiomyopathy (DCM) and associated
clinical phenotypes.
Background Mutations in several contractile proteins contribute to DCM, but definitive evidence for the roles of most sarco-
mere genes remains limited by the lack of robust genetic support.
Methods Direct sequencing of 6 sarcomere genes was performed on 334 probands with DCM. A novel D230N missense
mutation in the gene encoding alpha-tropomyosin (TPM1) was identified. Functional assessment was performed
by the use of an in vitro reconstituted sarcomere complex to evaluate ATPase regulation and Ca2 affinity as
correlates of contractility.
Results TPM1 D230N segregated with DCM in 2 large unrelated families. This mutation altered an evolutionarily con-
served residue and was absent in 1,000 control chromosomes. In vitro studies demonstrated major inhibitory
effects on sarcomere function with reduced Ca2 sensitivity, maximum activation, and Ca2 affinity compared
with wild-type TPM1. Clinical manifestations ranged from decompensated heart failure or sudden death in those
presenting early in life to asymptomatic left ventricular dysfunction in those diagnosed during adulthood. Nota-
bly, several affected infants had remarkable improvement.
Conclusions Genetic segregation in 2 unrelated families and functional analyses conclusively establish a pathogenic role for TPM1muta-
tions in DCM. In vitro results demonstrate contrasting effects of DCM and hypertrophic cardiomyopathy mutations in TPM1,
suggesting that specific functional consequences shape cardiac remodeling. Along with previous reports, our data
support a distinctive, age-dependent phenotype with sarcomere-associated DCM where presentation early in life is
associated with severe, sometimes lethal, disease. These observations have implications for the management of
familial DCM. (J Am Coll Cardiol 2010;55:320–9) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.017t
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Hilated cardiomyopathy (DCM) is an important cause of
eart failure (HF) and a leading indication for heart
ransplantation in children (1) and adults (2). During the
ast decade, there has been increasing recognition of the
mportant contribution of genetic etiologies in causing
idiopathic” DCM, with family studies suggesting that 30%
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f Cardiology, Children’s Hospital Boston, Boston, Massachusetts; ¶Harvard Med-
cal School–Partners Healthcare Center for Personalized Genetic Medicine, Cam-
ridge, Massachusetts; and the #Howard Hughes Medical Institute. Support for 2o 50% of the disease is inherited (3,4). However, clinical
anifestations may be highly variable and obscure the
dentification of familial disease.
See page 330
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January 26, 2010:320–9 Tropomyosin Mutations in DCMIn contrast to hypertrophic cardiomyopathy (HCM),
here sarcomere mutations cause the majority of disease (5),
he genetics of DCM are more diverse and not as well
efined. Mutations in a broad spectrum of genes have been
mplicated, including those encoding sarcomere proteins, com-
onents of the cytoskeleton, and mitochondrial proteins (3,6).
hrough comprehensive sequence analyses of sarcomere genes
n 334 DCM probands we identified 2 unrelated, multigen-
rational families with DCM that shared a variant in the gene
ncoding alpha-tropomyosin (TPM1). Alpha-tropomyosin is
n alpha-helical, coiled-coil homodimeric thin filament protein
hat participates in the Ca2 regulation of contraction and
cto-myosin interaction. Although TPM1 mutations are
nown causes of HCM, their pathogenicity in DCM has been
nconclusive because they have previously been identified only
n individual patients (7).
We report genetic segregation of a TPM1 mutation and
ts in vitro functional consequences on sarcomere function.
ogether these data provide strong evidence that TPM1
utations are pathogenic in DCM and extend knowledge
bout the pathogenesis and clinical course associated with
arcomere gene mutations.
ethods
enetic analysis. Genomic DNA was isolated from blood
y the use of standard methods (6) in probands with DCM.
irect DNA sequence analysis of all coding regions and
ntron/exon boundaries was performed in 6 sarcomere
enes: myosin binding protein-C (MYBPC3); beta-myosin
eavy chain (MYH7); cardiac troponin-T (TNNT2); cardiac
roponin-I (TNNI3); alpha-tropomyosin (TPM1); and
lpha-actin (ACTC1). To calculate the statistical likelihood
hat a genetic variant was associated with disease, logarithm
base 10) of odds (i.e., LOD) scores were calculated by the
se of Vitesse (version 2.0, Bournemouth, Dorset, United
ingdom) for Mac/PC, assuming 80% DCM penetrance at
0 years and an allele frequency 0.005. Haplotype analysis
as performed to determine family relatedness by charac-
erizing flanking single nucleotide polymorphisms in rele-
ant families.
ctin–tropomyosin-activated myosin ATPase assay. Bac-
erial expression constructs in pMW172 encoding hu-
an wild-type and D230N (mutant) Ala-Ser-alpha-
ropomyosin were created by 2-step polymerase chain reac-
ion site-directed mutagenesis. The Ala-Ser N-terminal
ddition to TPM1 compensates for the absence of
-terminal acetylation in the bacterially produced peptide
8). Mutant or wild-type Ala-Ser-alpha-tropomyosin were
xpressed with wild-type troponin I, troponin T, and
roponin C in BL21 (DES) pLysS Escherichia coli cells and
ubsequently purified according to established protocols (9).
ctin and myosin subfragment-1 (S-1) were obtained from
abbit skeletal muscle by standard procedures (10). Wild-
ype cardiac troponin complex was reconstituted from indi-
idual subunits by the use of stepwise dialysis and gel nltration as previously described
11). Thin filaments were recon-
tituted at an actin, Ala-Ser-
lpha-tropomyosin, and tropo-
in ratio of 7:1:1, respectively.
Assays were performed as pre-
iously described with the use of
.5-mol/l myosin S-1 and thin
laments reconstituted with the
se of 3.5-mol/l actin, 0.5-
mol/l tropomyosin, and 0.5-
mol/l troponin in 50-mmol/l
Cl, 5-mmol/l piperazine-
,N=-bis(2-ethanesulfonic acid),
.87-mmol/l MgCl2, and 0.25
mol/l dithiothreitol, pH 7.0, at 37°C. The free Ca2
oncentration was set by the use of 1-mmol/l ethylene glycol
etraacetic acid and the appropriate concentration of CaCl2
s previously described (11). Phosphate release was deter-
ined colorimetrically by standard protocols.
easurement of Ca2 affinity by the use of 2-[4=-(iodo-
cetamido)aniline]-naphthalene-6-sulfonate (IAANS)
roponin. Thin-filament Ca2 affinity was measured by the
se of IAANS label bound to Cys35 of recombinant human
roponin C (12); a reporter of Ca2 binding to the low-
ffinity site of troponin C (site II) (12). Thin filaments were
econstituted with 21-mol/l actin, 3-mol/l Ala-Ser-
lpha-tropomyosin, and 3-mol/l IAANS troponin. The
nal buffer concentration of ethylene glycol tetraacetic acid
as 1 mmol/l, and the free Ca2 concentration was set by
se of the appropriate concentration of CaCl2 as previously
escribed (12).
Steady-state fluorescence measurements (excitation 325 nm,
mission 455 nm) were made with the use of a RF-1501
pectrofluorometer (Shimadzu, Kyoto, Japan) at 22°C. The
hange in fluorescence (F) was monitored as the Ca2 was
itrated with final F values adjusted for the difference in assay
ix volume after each incremental addition of 10 mmol/l
aCl2. The adjusted and normalized F was plotted as a
unction of Ca2 concentration and the resultant curves fitted
o the Hill equation, a measure of the cooperativity of binding
etween Ca2 and the thin filament.
linical evaluation. Families with apparent familial DCM
ere recruited for genetic research. Family members were
valuated through history, physical examination, electrocar-
iography, and echocardiography. Echocardiographic di-
ensions were represented as z-scores for subjects younger
han 16 years of age and left ventricular end-diastolic
nternal diameter (LVIDD z-score 2.0 was considered
nlarged. The left ventricular ejection fraction (LVEF) was
alculated by use of the modified Simpson’s method. Sub-
ects were considered affected with DCM if they had any of
he following: clinical HF with left ventricular (LV) en-
argement or systolic dysfunction; asymptomatic LV en-
argement, that is, LV dimensions greater than the reference
Abbreviations
and Acronyms
DCM  dilated
cardiomyopathy
HCM  hypertrophic
cardiomyopathy
HF  heart failure
LV  left ventricular/
ventricle
LVIDD  left ventricular
end-diastolic internal
diameter
LVEF  left ventricular
ejection fractionormal dimensions in adults (13) or z-score 2 in children;
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Tropomyosin Mutations in DCM January 26, 2010:320–9r asymptomatic LV systolic dysfunction (LVEF 55%).
linical information on deceased subjects was obtained
rom their relatives and medical records whenever possible.
ll subjects provided informed consent in accordance with
he guidelines of the University of Chicago and Brigham
nd Women’s Hospital Human Subjects Committees.
tatistical analysis. SAS version 9.1 (SAS Institute, Cary,
orth Carolina) was used to generate Kaplan-Meier curves
o describe disease penetrance and event-free survival. Sta-
istically significant differences in Ca2 affinity and myosin
TPase activity were determined by the use of an unpaired
tudent t test (InStat, GraphPad Software Inc., La Jolla,
alifornia), with significance values defined as p  0.05.
esults
enetic analysis. A total of 334 subjects with DCM
nderwent sarcomere gene sequence analysis. A guanine to
denine (GA) substitution at residue 688 in the gene
ncoding alpha-tropomyosin (TPM1) was identified in 2
robands with familial disease (Online Fig. 1). This variant
s predicted to substitute a highly conserved, negatively
harged aspartate residue (D, position 230) (Online Table
) with a neutral asparagine (N) on the surface of tropomy-
sin (Fig. 1) (14).
TPM1 D230N segregated with DCM in 2 large Cauca-
ian families (Figs. 2A and 2B). Haplotype analysis was
erformed by characterizing flanking single nucleotide poly-
orphisms, which are found to occur at frequencies of 24%
nd 52%, respectively, in the general population. Disease
aplotypes were different in the 2 families (Fig. 2C),
ndicating that the families were unrelated and that TPM1
230N arose independently in each family.
The TPM1 D230N variant was present in all affected
embers in families A and B and absent from 21 of 25
naffected adult family members as well as 1,000 unre-
ated Caucasian control chromosomes. The combined cal-
ulated LOD score was 5.22. Therefore, we concluded that
PM1 D230N caused DCM in these 2 unrelated families.
n vitro alpha-tropomyosin functional studies. To inves-
igate the functional impact of TPM1 D230N, Ca2 regu-
ation of actin-tropomyosin–activated myosin S-1 ATPase
as evaluated as an in vitro correlate of contraction. Thin
laments reconstituted with wild-type Ala-Ser-alpha-
ropomyosin had a maximally activated rate of ATP turn-
ver of 4.08  0.01 s1. The concentration of Ca2 at
alf-maximal ATP-turnover (pCa50) was 6.47  0.02 (n 
) (Fig. 3A). In contrast, thin filaments reconstituted with
230N Ala-Ser-alpha-tropomyosin produced a lower max-
mum ATPase turnover rate (2.95  0.11 s1, n  3, p 
.001) and reduced Ca2 sensitivity (pCa50  6.20  0.04,
 3, p  0.05) (Fig. 3A). Filaments reconstituted with a
:1 mixture of wild-type/D230N Ala-Ser-alpha-
ropomyosin (the expected ratio in situ) also showed a
epressed maximally activated rate (3.26  0.21 s1,Figure 1 Molecular Model of Alpha-Tropomyosin
Alpha-tropomyosin is an alpha-helical coiled-coil that interacts with actin (violet
functional domains) and troponin T (blue). The locations of mutations associ-
ated with dilated cardiomyopathy (yellow) and hypertrophic cardiomyopathy
(green) are indicated. The D230N mutation is shown in red.
323JACC Vol. 55, No. 4, 2010 Lakdawala et al.
January 26, 2010:320–9 Tropomyosin Mutations in DCMFigure 2 Pedigrees and Haplotype Analysis of Families With Autosomal-Dominant DCM Due to D230N Mutation in Alpha-Tropomyosin
Pedigrees are shown for 2 unrelated families (family A [A] and family B [B]) with dilated cardiomyopathy (DCM). Squares indicate male family members, circles indicate
female family members, solid symbols indicate DCM, open symbols unaffected members, green symbols indicate uncertain clinical status, and slashes indicate
deceased members. Genotype results are indicated by ()  D230N present and ()  mutation absent. *Sudden cardiac death. (C) Haplotype analysis indicates that
the families are unrelated and that the D230N (688GA) TPM1 mutation arose independently in these families. Several family members from each kindred were geno-
typed at 4 loci in the TPM1 gene (rs4775613, rs4775614, rs1071646, rs4774472), comprising 4 common haplotypes in Caucasians (A, B, C, D) as described by Hap-
Map. The D230N mutation (fam variant) is shown in red with an asterisk.
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Tropomyosin Mutations in DCM January 26, 2010:320–9 0.001) and Ca2 sensitivity (pCa50 6.20 0.07, n
, p  0.05). The maximally inhibited rate at pCa 8.5 (0.75
0.02 s1) was not significantly affected by the presence of
he mutation.
The functional impact of this TPM1 D230N mutation is
trikingly different than a TPM1 mutation that causes
CM (D175N) (15). Thin filaments reconstituted with the
CM-mutant protein resulted in regulation with greater
a2-sensitivity (pCa50  6.58  0.04, n  3, p  0.05)
nd increased maximum ATP turnover (4.55 0.09 s1, n
Figure 3 Functional Properties of the D230N Mutation in Alpha
In vitro functional analyses of the D230N mutant alpha-tropomyosin show that at a
function and Ca2 affinity. (A) Ca2 sensitivity of thin-filament regulation of actin-t
ATPase turnover and pCa50 were significantly reduced (p  0.05) in the DCM muta
increased (p  0.05) in the HCM mutant protein (D175N). (B) Ca2 binding to the
reconstituted thin filaments containing D230N alpha-tropomyosin DCM mutant was si
D175N HCM mutant was associated with significantly increased Ca2 affinity (p  0.0, p  0.001) relative to wild-type tropomyosin (Fig. 3A). iTo determine whether the observed decrease in Ca2
ensitivity of contractility was due to an actual change in
a2 affinity rather than an apparent change caused by
ltered troponin-tropomyosin switching, thin filaments
ere reconstituted with the use of actin, IAANS-labeled
roponin C, and wild-type, D230N, or a 1:1 wild-type/
CM-mutant mixture tropomyosin. Wild-type thin fila-
ents bound Ca2 with a pCa50 of 6.24  0.02 with a Hill
oefficient (nH) of 1.74  0.12 (Fig. 3B). In contrast, there
as a dramatic decrease in the affinity of filaments contain-
omyosin
tivating-level of Ca2, the D230N mutation resulted in diminished sarcomere
yosin–activated myosin ATPase activity. Compared with the wild type, maximal
ha-tropomyosin (D230N). In contrast, both parameters were significantly
lament causes a decrease in spectrofluorescent intensity. The Ca2 affinity of
tly reduced (p  0.001) compared with wild-type alpha-tropomyosin. In contrast the
M  hypertrophic cardiomyopathy; other abbreviations as in Figure 2.-Trop
ny ac
ropom
nt alp
thin fi
gnifican
5). HCng D230N (pCa50 4.76 0.09; p 0.001), and the Hill
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January 26, 2010:320–9 Tropomyosin Mutations in DCMoefficient was also significantly reduced (nH 0.85 0.10;
 0.001) (Fig. 3B), indicating decreased cooperativity of
a2 binding. Experiments in which we used the 1:1
ild-type/DCM-mutant mixture also showed reduced
a2 affinity (pCa50  5.54  0.08) and lower cooperativity
nH  1.04  0.23 p  0.001) (data not shown in figure).
n contrast, thin filaments reconstituted with the HCM
utant protein were found to have significantly increased
a2 affinity compared with wild-type tropomyosin (pCa50
.57  0.09; p  0.05), consistent with the increased Ca2
ensitivity observed in the ATPase assay (Fig. 3B).
linical features of TPM1 D230N. The clinical manifes-
ations and course of DCM in families A and B are
ummarized in Table 1. No family members with TPM1
230N had evidence of cardiac conduction disease, and
ith one exception, none had evidence of skeletal my-
pathy. Abnormal cardiac dimensions and contractile pa-
ameters were identified in 16 of 20 mutation carriers,
ndicating a penetrance of 80% for DCM in the 2 families.
s seen in Figure 4, the development of DCM occurred
ver a wide spectrum of ages. However, there were striking
ifferences in clinical course on the basis of age of presen-
ation, with adverse outcomes occurring early in life (Fig. 4).
amily A. Family A was notable for severe HF and sudden
eath in young children. Subjects I-2, III-10, and IV-7 died
uddenly at ages 3 years, 13 months, and 5 months,
espectively, without previous evidence of heart disease.
wo siblings, IV-5 and IV-8, presented with DCM and
dvanced HF at 5 months of age (LVEF 27% and 29%) and
ere given the presumptive diagnosis of myocarditis. In
V-5, adenovirus DNA was detected by polymerase chain
eaction on endomyocardial biopsy. Both had substantial
ecovery of LV systolic function and resolution of symptoms
fter receiving standard medical care at the time of presen-
ation (digoxin and furosemide). Notably IV-8, now age 21
ears, participates in marathons.
Subjects III-3 and IV-1 developed end-stage HF refrac-
ory to medical therapy as teenagers. III-3 presented at age
3 with refractory HF, underwent mitral and tricuspid valve
eplacement for functional regurgitation, and died weeks
ater of multisystem organ failure before genetic testing.
V-1 was asymptomatic when diagnosed with DCM at 7
ears during family screening but developed severe HF at
ge 17 years and underwent transplant at 18 years of age.
istologic examination of his explanted heart revealed
onspecific changes consistent with DCM, without myo-
yte disarray, marked fibrosis, or inflammation to suggest
ither end-stage HCM or myocarditis.
By contrast, 4 mutation carriers who presented in adult-
ood had mild clinical courses. Subjects III-4, III-7, and
II-12 developed mild exercise intolerance in their fifth
ecade. Clinical studies revealed mild-to-moderate LV
ystolic dysfunction and enlargement and symptoms re-
olved with medical management. II-6 was healthy before
n inferior myocardial infarction at 71 years. She was pubsequently found to have mild LV systolic dysfunction
LVEF 49%) and remains asymptomatic.
Four mutation carriers (subjects III-1, IV-4, IV-11,
V-15; ages 54, 16, 22, and 8 years, respectively), had
symptomatic LV systolic dysfunction and/or enlargement.
hree adult mutation carriers (III-5, III-13, IV-2), were
ree of symptoms and had normal LV size and systolic
unction.
amily B. Young members of this family also presented
ith severe HF. Subject III-1 developed failure to thrive at
0 weeks of age and echocardiography revealed severe LV
ilation (LVIDD z-score 15.6) and systolic dysfunction
LVEF 15%). Transplantation was considered, but the
ubject had substantial recovery with basic medical therapy.
y age 8 years, she was asymptomatic with only mild LV
ystolic dysfunction (LVIDD z-score 1.3, LVEF 46%). At
ge 20 years, II-6 underwent cardiac transplantation shortly
fter presenting with refractory HF symptoms and severe
V systolic dysfunction (LVEF 20%).
Subject II-7 died of HF at age 12 years, before genetic
esting. In addition to DCM, he had congenital cataracts
nd skeletal muscle weakness. Post-mortem examination
emonstrated cardiomegaly with marked endocardial and
nterstitial fibrosis. Skeletal muscle analyses demonstrated
hronic myopathic changes but normal dystrophin staining
nd no inflammation, evidence of storage disease, tissue-
pecific atrophy, or fiber type grouping.
As in family A, the clinical course of mutation carriers in
amily B identified in adulthood was far less severe. I-1 had
nexplained syncope at age 56 years. Cardiac studies re-
ealed ventricular tachycardia and DCM (LVEF 25%),
hich improved with medical management. Three other
dults (II-2, II-3, and II-4, ages 38, 36, and 33 years,
espectively) had asymptomatic LV systolic dysfunction.
fter an uncomplicated pregnancy, II-4 had a mild
urther decrease in LVEF from 48% to 39%, improving
o 55% with institution of an angiotensin-converting en-
yme inhibitor.
iscussion
e identified a D230N missense mutation in TPM1 as the
ause of DCM in 2 unrelated multigenerational families.
nlike previously reported TPM1 variants (E45K, E40K)
ssociated with DCM in isolated subjects (7), we demon-
trate that dominant transmission of TPM1 D230N segre-
ates with disease and deleteriously impacts in vitro assays
f contractility, providing definitive evidence that TPM1
utations cause DCM. Furthermore, these functional stud-
es demonstrated that mutations in the same genes have
ifferent effects that may influence whether a phenotype of
CM or HCM develops. The clinical profile of these
amilies suggests a pattern for sarcomeric DCM in which
linical outcomes differ dramatically on the basis of age of
resentation.
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Tropomyosin Mutations in DCM January 26, 2010:320–9ivergent functional consequences of sarcomere mutations
ay shape different patterns of cardiac remodeling. Sar-
linical Characteristics of Affected Family Members on the Basis oTable 1 Clinical Characteristics of Affected Family Members on
Family Pedigree
Age at
Diagnosis*
Current Age or
Age at Death† D230N Sex
Cli
Fea
NYHA functional class II
A I-2 — 3 yrs† NA F SCD
A III-3 13 yrs 13 yrs† NA F NYHA I
HF d
A III-10 13 months 13 months† NA M SCD
A IV-1 7 yrs 26 yrs  M NYHA I
Txp
A IV-5 5 months 28 yrs  F NYHA I
impr
A IV-7 6 months 6 months† NA F SCD
A IV-8 5 months 21 yrs  F NYHA I
impr
B I-1 56 yrs 64 yrs  F VT
B II-6 20 yrs 24 yrs  M NYHA I
Txp
B II-7 9 yrs 12 yrs† NA M NYHA I
HF d
B III-1 10 weeks 8 yrs  F NYHA I
NYHA functional class II
A II-4 — 71 yrs  F NYHA I
A III-1 54 yrs 57 yrs  F NYHA I
A III-4 47 yrs 53 yrs  M NYHA I
A III-5 — 53 yrs  F NYHA I
A III-7 45 yrs 50 yrs  M NYHA I
A III-12 40 yrs 44 yrs  F NYHA I
A III-13 — 42 yrs  F NYHA I
A IV-2 — 23 yrs  F NYHA I
A IV-4 16 yrs 19 yrs  F NYHA I
A IV-11 22 yrs 24 yrs  M NYHA I
A IV-15 8 yrs 11 yrs  F NYHA I
B II-2 30 yrs 38 yrs  M NYHA I
B II-3 32 yrs 36 yrs  M NYHA I
B II-4 31 yrs 34 yrs  F NYHA I
No age provided for subjects without evidence of DCM. †Age at death.
DCM  dilated cardiomyopathy; HF  heart failure; LV  left ventricular/ventricle; LVEF  left v
ge 16 yrs; NA  not available; NYHA  New York Heart Association functional class; SCD  suomere mutations were initially characterized as the cause df HCM but, as demonstrated in this study, can also
ause DCM (6,16). The molecular mechanisms that
erity of Clinical PresentationBasis of Severity of Clinical Presentation
LVEF
(%)
LVIDD
(cm)/(z-score) Comments
— — No symptoms before SCD. No autopsy
performed.
— — Died of multisystem organ failure during HF
hospitalization.
— — No symptoms before SCD. Autopsy notable for
LV dilation.
9 8.6 Diagnosed during family screening and became
progressively symptomatic culminating in
cardiac transplantation at 18 yrs.
nt
27 4.2 (13.2) Severe HF as an infant with improvement after
medical therapy (LVEF now 50%).
— — SCD at age 6 months without previous symptoms.
Autopsy reported LV dilation.
nt
29 4.5 (15.2) Severe HF as an infant with improvement after
medical therapy (LVEF now 58%).
25 5.9 Presented with symptomatic VT and severe
DCM, which improved with medical therapy
(LVEF now 40%).
20 — Cardiac transplantation at age 20 yrs.
— — Presented with DCM at 9 yrs and died of HF at
12 yrs. Also had congenital cataracts and
skeletal weakness.
15 4.8 (15.6) Severe HF as an infant with improvement after
medical therapy (LVEF now 46%).
49 4.6 Asymptomatic. Mildly reduced LVEF identified
after myocardial infarction at 71 yrs.
40 5.5 Asymptomatic but LVEF decreased during
follow-up from 52% to 40%.
50 6.4 Minimal exercise intolerance developed at
age 48 yrs.
56 4.8 Asymptomatic without evidence of LV
enlargement or dysfunction.
50 5.7 Minimal exercise intolerance developed at
age 47 yrs.
50 5.6 Palpitations and mild LV enlargement/systolic
dysfunction without exercise limitation.
55 4.7 Asymptomatic without evidence of LV
enlargement or dysfunction.
59 4.8 Asymptomatic without evidence of LV
enlargement or dysfunction.
57 5.6 Asymptomatic with mild LV enlargement.
40 5.5 Asymptomatic but LVEF decreased during
follow-up from 50% to 40%.
51 4.2 Asymptomatic with mildly reduced LVEF.
45 5.1 Asymptomatic with mildly reduced LVEF.
35 6.4 Asymptomatic but moderately reduced LVEF
that decreased during follow-up from 42% to
35% with concomitant 5-mm increase in
LVIDD.
39 5.6 Asymptomatic but LVEF decreased after
pregnancy from 48% to 39%, normalizing
with medical therapy (55%).
ar ejection fraction; LVIDD  left ventricular end-diastolic diameter z-score calculated for children
ardiac death; Txp  cardiac transplantation; VT  ventricular tachycardia.f Sevthe
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January 26, 2010:320–9 Tropomyosin Mutations in DCMevelops have not been clearly elucidated. Mutation
ocation does not appear to be critical. As shown in
igure 1, mutations that cause HCM and DCM are
losely interspersed and in the same functional domains
n tropomyosin. However, the in vitro functional conse-
uences of these mutations differ. Consistent with pre-
ious reports evaluating DCM mutations in thin filament
roteins (12), our results demonstrate that D230N alters
a2 regulation in tropomyosin by reducing Ca2 sen-
itivity, maximum activation, and Ca2 affinity. Experi-
ental models in which the investigators used mechan-
cally loaded cardiac muscle fibers (17) have also shown a
a2-desensitizing effect of thin filament mutations.
ollectively, these DCM mutations are predicted to
roduce a muscle intrinsically capable of producing less
orce at any activating Ca2 concentration. Left ventric-
lar dilation may represent a compensatory mechanism to
aintain stroke volume in the setting of reduced con-
ractility as the result of decreased force production
nd/or Ca2 affinity associated with the TPM1 mutation.
ctivation of the neurohormonal axis may also occur,
ulminating in progressive cardiac failure.
Notably, these functional changes are opposite to those
bserved for sarcomere mutations that ultimately give rise
o HCM in which Ca2 sensitivity is enhanced and
redicted to increase contractility (12). Figure 3 illus-
rates this contrast. Maximum ATPase activity, Ca2
ensitivity, and Ca2 affinity are decreased with the
230N DCM TPM1 mutation but increased with the
Figure 4 Clinical Outcomes in Carriers of the D230N Alpha-Tro
The presence of TPM1 D230N is associated with a high risk for developing DCM b
curve). DCM includes both symptomatic and asymptomatic left ventricular systolic
tion (Txp) were confined to young family members and distinctly absent from those
genotyping were assumed to be mutation carriers (G). Abbreviations as in Figure175N HCM TPM1 mutation. Moreover, previous tiophysical studies in which the investigators examined
he thick filament demonstrated a similar pattern. Force
eneration and ATPase activity are decreased in myosin
eavy-chain mutations associated with DCM but in-
reased in HCM-associated mutations (18). Collectively
hese results suggest that fundamental differences in the
unctional consequences of sarcomere mutations may
nderlie the very disparate patterns of remodeling ob-
erved in DCM and HCM, despite an apparently com-
on genetic etiology. We postulate that sarcomere mu-
ations that compromise force generation may lead to a
ilated phenotype, whereas a hypertrophic phenotype
ay arise from mutations that increase force generation.
distinctive age-dependent phenotypic profile of sarco-
ere mutation DCM. Consistent with previous descrip-
ions of DCM caused by sarcomere mutations, the clinical
rofiles of our families differ from both HCM caused by
arcomere mutations and DCM of other genetic etiologies,
either of which are characterized by severe disease in early
hildhood (19,20). As illustrated in Figure 4, marked
ge-dependent differences in outcomes were observed in our
families with TPM1 mutations. Presentation early in life,
rom infancy to adolescence, was not uncommon and was
ssociated with severe, sometimes lethal outcomes, includ-
ng sudden cardiac death and refractory HF leading to death
r transplantation. In contrast, a mild course was observed
n relatives diagnosed as adults.
The pattern of severe childhood but mild adult-onset
isease seen with the TPM1 D230N mutation is similar to
osin Mutation
r a wide spectrum of ages, ranging from infancy to the sixth decade (black
n and/or dysfunction. Severe clinical outcomes, cardiac death, and transplanta-
nting in adulthood (red curve). *Subjects who experienced cardiac death beforepomy
ut ove
dilatio
prese
2.hat reported with 2 other sarcomere genes, MYH7 and
T
d
l
t
e
i
s
m
u
n
a
p
t
t
m
m
l
c
m
i
t
l
m
a
m
p
f
C
W
D
a
i
t
b
m
o
m
t
s
t
a
w
t
h
o
o
d
m
c
i
D
m
s
s
t
d
D
t
fi
A
T
f
R
B
M
R
1
1
1
1
328 Lakdawala et al. JACC Vol. 55, No. 4, 2010
Tropomyosin Mutations in DCM January 26, 2010:320–9NNT2 (6,16,21). Affected members of these families also
emonstrated marked LV dysfunction and HF very early in
ife, with either striking recovery or progression to death or
ransplantation, whereas those identified in adulthood gen-
rally had mild disease. This clinical profile differs mean-
ngfully from that observed in other genetic causes of DCM,
uch as that caused by lamin A/C or phospholamban
utations where manifestations typically do not develop
ntil adulthood and are progressive (19,22). The mecha-
isms underlying the different clinical course in children and
dults have not been defined; however, recognizing this
attern as a feature of sarcomere mutation DCM is impor-
ant for appropriate family evaluation and intervention.
Moreover, although early presentation with DCM was
ypically severe, there was potential for remarkable improve-
ent because 3 of 5 affected infants with the TPM1
utation had striking recovery of LV function. We specu-
ate that the underlying TPM1 mutation may confer sus-
eptibility to myocardial injury due to viral infections (e.g.,
yocarditis) or systemic illness that could account for the
nitially dramatic clinical presentations. Factors leading to
he marked improvement in a subset of these children are
ess clear and unlikely to be related solely to receiving basic
edical therapy. However, further elucidation of the mech-
nisms that allowed recovery in this primary genetic cardio-
yopathy may provide important insights regarding the
athogenesis and management of more common secondary
orms of DCM and HF.
onclusions and Clinical Implications
e present robust evidence that mutations in TPM1 cause
CM and further characterization of disease pathogenesis
nd clinical course. In vitro functional studies provide
nsight into the phenotypic development of cardiomyopa-
hy. Although sarcomere mutations are a common cause of
oth HCM and DCM, the functional consequences appear
arkedly different in these 2 diseases, with opposite effects
n Ca2 affinity, sensitivity, and contractility. These funda-
ental differences may play an important role in shaping the
ype of cardiac remodeling that arises.
The pattern emerging in these and other DCM families
uggests that sarcomere mutations may result in a distinc-
ive, age-dependent clinical profile. Early presentation is
ssociated with severe, sometimes-lethal disease, although
ith potential for substantial recovery. In contrast, presen-
ation in adulthood is generally benign. These observations
ave several important clinical implications. In pediatric-
nset HF, inherited causes of cardiomyopathy often are
verlooked in favor of a presumptive diagnosis of myocar-
itis (23), particularly if there is dramatic clinical improve-
ent. However, in these 2 families, childhood disease was
aused by the TPM1 mutation. This finding highlights the
mportance of considering genetic etiologies in new-onset
CM in children and the need to consider at-risk family
embers. Furthermore, these findings have relevance for
1creening families with DCM. Current guidelines for family
creening in HCM recommend that formal evaluation
ypically begins in adolescence (24). However, the severe
isease manifestations observed in young children with
CM suggest that the identification of a sarcomere muta-
ion should prompt aggressive screening for DCM in all
rst degree relatives, beginning early in life.
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